


FlowflexTM



SARS-CoV-2 Antigen Rapid Test

A rapid, highly reliable and affordable kit, providing an aid in early diagnosis of individuals who are suspected of COVID-19 by their healthcare provider and who are asymptomatic.

The Global Leader of Rapid Test with **26** Years Experience.



Fast



Reliable



Easy to Use



User friendly



CE Marked

ACON[®]

ACON Biotech (Hangzhou) Co., Ltd.

Flowflex SARS-CoV-2 Antigen Rapid Test

The Flowflex SARS-CoV-2 Antigen Rapid Test is a lateral flow chromatographic immunoassay for the qualitative detection the nucleocapsid protein antigen from SARS-CoV-2 in nasal and nasopharyngeal swab specimens directly from individuals who are suspected of COVID-19 by their healthcare provider within the first seven days of the onset of symptoms. The SARS-CoV-2 Antigen Rapid Test can also test specimens from asymptomatic individuals.

- Nasal and Nasopharyngeal swab specimens
- Results at 15 min.
- Excellent performance compared to molecular methods
- Room temperature storage

Clinical Performance

Nasal Swab Specimens

The performance of SARS-CoV-2 Antigen Rapid Test was established with 605 nasal swabs collected from individual symptomatic patients who were suspected of COVID-19. The results show that the relative sensitivity and the relative specificity are as follows:

Clinical Performance for SARS-CoV-2 Antigen Rapid Test

Method	Results	RT-PCR		Total Results
		Negative	Positive	
SARS-CoV-2 Antigen Rapid Test	Negative	433	5	438
	Positive	2	165	167
Total Results		435	170	605
PPA: 97.1%(93.1%-98.9%)*		NPA: 99.5%(98.2%-99.9%)*		OPA: 98.8%(97.6%-99.5%)*

PPA-Positive Percent Agreement; **NPA**-Negative Percent Agreement; **OPA**-Overall Percent Agreement, *95% Confidence Intervals

Stratification of the positive samples post onset of symptoms between 0-3 days has a positive percent agreement (PPA) of 98.8% (n=81) and 4-7 days has a PPA of 96.8% (n=62).

Positive samples with Ct value ≤ 33 has a higher positive percent agreement (PPA) of 98.7% (n=153).

Nasopharyngeal Swab Specimens

The performance of SARS-CoV-2 Antigen Rapid Test was established with 299 nasopharyngeal swabs collected from individual symptomatic patients who were suspected of COVID-19. The results show that the relative sensitivity and the relative specificity are as follows:

Clinical Performance for SARS-CoV-2 Antigen Rapid Test

Method	Results	RT-PCR		Total Results
		Negative	Positive	
SARS-CoV-2 Antigen Rapid Test	Negative	175	3	178
	Positive	1	120	121
Total Results		176	123	299
PPA: 97.6% (92.8%-99.5%)*		NPA: 99.4% (96.5% - 99.9%)*		OPA: 98.7% (96.5% - 99.6%)*


PPA-Positive Percent Agreement; **NPA**-Negative Percent Agreement; **OPA**-Overall Percent Agreement, *95% Confidence Intervals.

Materials Provided


- Test Cassettes
- Extraction Buffer Tubes
- Negative Control Swab
- Nasal Swabs or Nasopharyngeal Swabs
- Package Insert
- Specimen Collection Guide
- Positive Control Swab

Specimen Collection


Nasal Swabs



Nasopharyngeal Swabs



Test Procedure and Interpretation



Ordering Information

Product Name	Catalog No.	Format	Specimen	Package
Flowflex SARS-CoV-2 Antigen Rapid Test	L031-11815 ✓	Cassette	Nasal and Nasopharyngeal swabs	25 Tests/Kit

✓ CE marked



www.aconbio.com

ACON Biotech (Hangzhou) Co., Ltd.
 No.210 Zhenzhong Road, West Lake District,
 Hangzhou, P.R.China, 310030
 Tel: +86-571-8118 9706
 Fax: +86-571-8777 5781
 Email: information@aconlab.com.cn